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Abstract
Staphylococcus aureus is a major cause of hospital-acquired infections. The multi-drug
resistant nature of certain S. aureus strains makes the discovery of new drug targets for S. aureus
vital. A newly discovered virulence factor from S. aureus was described as an ortholog of NagD
from E. coli, a member of the nitrophenyl phosphatase family of the HAD (Haloacid
Dehalogenase) superfamily. This thesis will show that this virulence factor is not an ortholog of
NagD UMPase from E. coli, but rather a phosphoglycolate phosphatase (PGPase). If
phosphoglycolate accumulates in the cell, it will inhibit the glycolytic enzyme triose phosphate
isomerase (TPI). In S. aureus, TPI also serves as an adhesion protein that can bind to host cells;
phosphoglycolate would interfere with this adhesion process and thus make it harder for
S. aureus to infect host cells. Thus, this S. aureus PGPase may act as a virulence factor by
degrading the TPI inhibitor phosphoglycolate. We cloned the gene, expressed and purified the
protein, and determined and characterized its activity. We have subcloned this PGPase into a
His•Tag vector, purified the protein using nickel affinity and size exclusion chromatography, and
characterized enzymatic activity, optimal conditions (substrate, pH, and metal usage), and
kinetics.
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I. Introduction
i. History and Importance of Enzymology
Throughout the years, scientists have endeavored to gain insight into how biochemical
reactions that would normally take thousands to billions of years, occur in a drastically shorter
timescale that allow for life1. Enzymes are what give life on Earth this unique ability. The study
of enzymes is important in the understanding of life and the advancement of medicine. The
commercial use of enzymes by man dates back thousands of years; in fact, the use of enzymes is
noted in an ancient Bablyonian text from 2100 BCE2. It wasn’t until studies in the mid to late
1700’s that enzymatic activity would be described by René Antoine Ferchault de Réaumur and
Lazzaro Spallanzani, and almost a century later for Wilhelm Friedrich Kühne to coin the term
“enzyme” from the Greek word enzumos, a term that refers to leavening bread2.
ii. The Enzyme Function Initiative
In the past two decades, there has been a concerted effort to sequence as many whole
genomes of as many organisms as possible (whole genome sequencing projects) as well as
determine as many unique protein structures as possible (Structural Genomics Initiative3), but
what has been lacking is the functional annotation and characterization of all of these proteins.
Another problem is that a surprisingly large number of proteins in databases, such as the Protein
Data Bank, have been misannotated, meaning they have been assigned functions that they do not
actually possess and their real function has still to be elucidated. The Enzyme Function Initiative
(EFI) was established to solve this problem. The EFI is a consortium of researchers whose goal
is to determine the biologically relevant function of proteins that have not yet been characterized
or have been misannotated4. The EFI is accomplishing this task by the integration of
computational and biological methods, and is separated into Cores and Bridging Projects. The
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Cores are: genome searching (to update membership of superfamilies), protein expression (high
throughput cloning, expression, and purification of chosen proteins), structural characterization
(determination of x-ray crystal structure of purified proteins), computational studies
(development and application of computational methods to infer enzymatic activity from protein
structure), microbiology studies (to determine in vivo function), and data dissemination (to
update and maintain the EFI website and database so that the data gathered is readily
accessible)4. The EFI has five Bridging Projects that are essentially the investigation of five
different enzyme superfamilies: amidohydrolase, enolase, glutathione transferase, isoprenoid
synthase, and haloacid dehalogenase (more recently also referred to as haloalkanoic acid
dehalogenase) superfamilies4.
iii. Haloacid Dehalogenase Superfamily
The Haloacid Dehalogenase (HAD) superfamily of enzymes is a large group encompassing
over 3000 different enzymes with members found in the proteomes of organisms from all three
domains of life5,6. This superfamily was named for the first enzymes of this superfamily that
were characterized,

the

prokaryotic haloacid dehalogeases7.

Including the haloacid

dehalogenases, there are three other classes of enzymes that compose the HAD superfamily:
phosphatases (including ATPases), phosphonatases, and phosphomutases5,6. Ninety-nine percent
of members that have been uncovered thus far are phosphatases, thus a majority of HAD
superfamily members perform the phosphate monoesterase function6. The biological roles of
these enzymes vary, ranging from secondary metabolism to signal transduction to DNA repair 8.
Figure 1 shows the reactions for each class of enzymes5; for each, an aspartate residue is utilized
as the nucleophile.
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Figure 1: Mechanisms for HAD superfamily members. The four reaction mechanisms above show how the
members of the HAD superfamily utilize a catalytic aspartic acid for catalysis.

The basic structure of the core domain of all HAD superfamily members is the same (shown
in Figure 2)5,6,8. This core domain consists of a three layered α/β sandwich that is composed of
repeating β-α units, characterized as the Rossmann fold5,6,8. Two structural features differentiate
the Rossmann fold in the HAD superfamily from other types of Rossman folds: the “squiggle”
and “flap” elements defined by Burroughs et al5. The “squiggle” is comprised of six residues that
almost create a single helical turn. The “flap” is downstream of the “squiggle” and is a β-hairpin
turn projecting out of the core domain5,6.

3

Figure 2: General HAD structure. Shown is the general structure found in members of the HAD superfamily. The
characteristic Rossmann fold is shown along with the squiggle (pink) and flap (green) elements. The position of the
four conserved motifs and cap domain insertion sites are also shown.

Sequence alignments of HAD superfamily members show ~15% similarity overall and reveal
the conservation of four motifs that contain key catalytic amino acids6. Note here that the term
“motif” as coined by Koonin and Tatusov refers to the conserved amino acid sequences among
HAD superfamily members and differs from the more standard definition of “motif” in protein
structures7. Motif 1 contains the sequence DxD, which is two aspartic acid residues separated by
any amino acid5,6,8. The carboxylate groups of both of the aspartates coordinate to a divalent
metal ion (M2+) cofactor as well as playing other key roles in catalysis8. All phosphotransferases
within the superfamily possess maximal activity with Mg2+; however, Zn2+, Co2+, and Mn2+ can
also be utilized9. The divalent metal ion cofactor shields the negative charge of the nucleophilic
aspartate side chains and stabilizes the phosphoryl group of the substrate (see Figure 3)10. A
serine or threonine residue within motif 2 and a lysine residue within motif 3 serve to stabilize
the reaction intermediates of the hydrolysis reaction5,6,8. Motif 4 can be one of three sequences
depending on the HAD superfamily enzyme in question: DD, GDxxxD or GDxxxxD5. These
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aspartate or glutamate residues also serve to coordinate the M2+ cofactor with motif 1. The amino
acids within these four motifs are found in the active site (Figure 3) and it is one of the aspartates
within motif 1 that is responsible for the dephosphorylation reaction. The first aspartate
nucleophilically attacks the phosphate group, allowing the –OR group of the substrate to leave,
usually resulting in the formation of a hydroxyl group10,11. The second aspartate residue
deprotonates a nearby water molecule and the resulting hydroxide ion attacks the
phosphoaspartyl enzyme intermediate causing the first aspartate to act as a leaving group thus
generating free phosphate11. The nucleophilic aspartate is beneficial as aspartate can act as a
good leaving group as well as a good nucleophile11.

Figure 3: Schematic of HAD family active sites. The schematic shows the location of the four conserved motifs
and how each coordinates with either the divalent metal ion cofactor or substrate.
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iv. Subfamilies of HAD Superfamily
The HAD superfamily is separated into three subclasses based on the presence of insertions
called cap domains that are in addition to the catalytic core domain (see Figure 2)5,6,8. Subfamily
I cap domains contain an α-helical-bundle domain inserted into the flap element indicated by the
green line in Figure 2. This bundle varies in complexity among specific enzymes and ranges
from a basic bi-helical α-hairpin to globular multi-helical bundles5. This insertion would “close”
over the active site upon substrate binding and “open” to allow the leaving group to exit; for this
reason, subfamily I members act predominantly on small substrates6. Subfamily I consists of
haloacid dehalogenases, phosphonatases, and phosphomutases5,6. Subfamily II contains a cap
domain that is typically composed of α/β sandwiches with a core β-sheet. This insertion site is
indicated in Figure 2 as an orange line. This cap domain is not mobile like the subfamily I cap
domain; instead, the insertion forms a cavernous structure that is sealed off by movement of the
“squiggle-flap” motif only, thus subfamily II members also act upon small substrates5. All of the
enzymes in subfamily II are phosphatases. The final class, subfamily III, contains no large
insertion, thus no cap, leaving the active site exposed on one side to the solvent5,8. For this
reason, subfamily III enzymes typically catalyze reactions with larger substrates; enzymes in this
subfamily are protein phosphatases5.
Subfamily II can be further broken down as NagD-like proteins (subfamily IIa) and Coflike proteins (subfamily IIb)5. They are classified together due to the fact that they have the same
insertion site for their cap domain. The distinguishing characteristic between subfamily IIa and
subfamily IIb is the arrangement of the β sheets of the cap domain. Subfamily IIa members have
four parallel β-sheet strands whereas subfamily IIb members have three anti-parallel β-sheet
strands5. A majority of HAD phosphatases are within subfamily IIb; fewer enzymes fall into
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subfamily IIa. All members of subfamily IIa are capable of hydrolyzing a phosphate from paranitrophenyl phosphate, hence the name, the p-nitrophenyl phosphatase (pNppase) subfamily of
the HAD superfamily.
v. The pNppase Subfamily
The HAD superfamily was identified by Koonin et al. through the computer analysis of
bacterial haloacid dehalogenases using an iterative approach to search sequence databases7. This
approach utilized BLAST searches, alignments, and other bioinformatic tools with the goal of
delineating a superfamily and potential subfamilies. One subfamily that was identified through
cluster analysis based on BLAST scores was the pNppase subfamily (see Figure 4)7. At that time
the only enzymes of this subfamily that had been characterized were two orthologs from two
different yeasts, Saccharomyces cerevisiae and Schizosaccharomyces pombe, and even the
natural substrates for those enzymes were not known; activity had only been found for the nonnatural substrate pNpp. The first member of the subfamily to be identified with activity on a
natural substrate was YZGD. YZGD from Paenibacillus thiaminolyticus is a pyridoxal
phosphatase (PLPase) with a second domain that belongs to the NUDIX hydrolase superfamily12.
A human PLPase, without a NUDIX domain, has also been characterized and is believed to play
a role in vitamin B6 metabolism in erythrocytes13. NagD from E. coli is a UMPase and it is
hypothesized to be involved in the regulation of cell wall and polysaccharide biosynthesis12 as
well as pyrimidine homeostasis14. NagD is the first enzyme of the pNppase subfamily for which
the structure has been determined8. AraL from Bacillus subtilus has been identified as a sugar
phosphatase15. Of particular interest to us are the phosphoglycolate phosphatase (PGPase)
members of the subfamily, which is the topic of the next section.
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Figure 4: Sequence alignment of pNppase family members. The amino acid sequences of phosphoglycolate
phosphatase from S. aureus, S. cerevisiae (Pho13), S. pombe, and C. rinhardtii (PGP2), NAGD from E. coli, AraL
from B. subtilits, pyridoxial phosphatase (PLPase) from humans, and YZGD from P. thiaminolyticus were aligned
using CLUSTALX. Similar and identical amino acids are in boldface, with identical amino acids indicated with ‘*’.
Gaps in the amino acid sequences are inserted to optimize alingments (indicated by ‘-’). Motifs I, II, II, and IV of the
HAD superfamily are underlined and labeled.
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vi. Phosphoglycolate Phosphatases
Phosphoglycolate phosphatase (PGPase) is responsible for the cleavage of phosphate from 2phosphoglycolate (2-PG) (Figure 5). In photosynthetic organisms, 2-phosphoglycolate is
generated by Rubisco (ribulose-1,5-bisphosphate carboxylase / oxygenase)16,17. In carbon
dioxide-rich environments, Rubisco catalyzes the reaction of carbon dioxide with ribulose-1,5bisphosphate to generate 2 molecules of 3-phosphoglycerate18. 3-phosphoglycerate is converted
to

glyceraldehyde

3-phosphate

(G3P)18,

an

intermediate

of

glycolysis.

Figure 5: Chemical reaction of phosphoglycolate phosphatase activity. Shown is the hydrolysis of
2-phosphoglycolate releasing phosphate and glycolate. Figure was made using ChemSketch.

Rubisco is also capable of utilizing molecular oxygen to react with ribulose-1,5bisphosphate, a process known as photorespiration18. The reaction between oxygen and ribulose1,5-bisphosphate generates one molecule of 3-phosphoglycerate and one molecule of
2-phosphoglycolate. The 3-phosphoglycerate enters glycolysis, but 2-phosphoglycolate appears
to be a dead-end metabolite and thus must be degraded by PGPase. The resulting glycolate can
be converted to glycine, which is utilized by the cell18. Studies have shown that PGPase-deficient
strains of Arabidopsis thaliana, Hordeum vulgare (barley), and Chlamydomonas reinhardtii
(algae) can only grow under high CO2 conditions16. This indicates that an accumulation of
2-phosphoglycolate is detrimental to the cell. One reason that this accumulation could be harmful
is that 2-phosphoglycolate is a strong inhibitor of triose phosphate isomerase (TPI), an important
9

glycolytic enzyme; 2-phosphoglycolate acts as a transition state analog and binds 100 times more
tightly to TPI than do its substrates19,20. The crystal structure of 2-phosphoglycolate bound to the
active site of TPI has been solved to a resolution of 2.5 Å19. Rubisco utilizes CO2 and O2 in a 4:1
ratio in normal atmospheric conditions so PGPase must be expressed to ensure phosphoglycolate
does not inhibit TPI, blocking glycolysis or gluconeogenesis18.
The only confirmed way of producing phosphoglycolate in vivo is in the above
photorespiratory pathway, but the presence of PGPase in non-photosynthetic organisms indicates
2-phosphoglycolate must be produced by a non-photosynthetic means as well. Exactly how
2-phosphoglycolate is produced in non-photosynthetic organisms has yet to be established. Of
the PGPases from non-photosynthetic organisms, a few have been studied in depth.
The PGPase from S. cerevisiae, Pho13, may play a role in xylose metabolism as S. cerevisiae
that lack Pho13 are more fit for growth with a xylose carbon source21–23. Xylose is not a natural
carbon source for S. cerevisiae, however engineered strains that include key enzymes such as
xylose reductase and xylitol dehydrogenase can metabolize xylose to ethanol (a key process in
the development and production of biofuels since xylose composes ~40% of cellulosic
biomass24).
In E. coli, the gph gene encodes a PGPase that appears to be involved in DNA repair17. In the
repair process, 3’-phosphoglycolate ends that are generated by oxidative damage to DNA are
repaired to generate free 2-phosphoglycolate17. When E. coli was treated with bleomycin (an
agent that oxidatively damages DNA) levels of 2-phosphoglycolate were significantly increased
in gph mutants, as compared to wild type E. coli17.

10

In erythrocytes, 2-phosphoglycolate is a potent effector of the bisphosphoglycerate shunt (a
major modifier of the oxygen affinity of hemoglobin)25. 2-phosphoglycolate may be produced by
the phosphorylation of glycolate via pyruvate kinase26.
vii. History and Characteristics of Staphylococcus aureus
S. aureus is a gram-positive bacterium and a facultative anaerobe; the bacteria is capable of
growing in aerobic and anaerobic conditions, switching between aerobic respiration and
fermentation27. Prior to 1880, the cause of infection after surgery was not precisely known.
When Swedish surgeon Alexander Ogston inoculated chicken eggs with pus from patients, he
observed clusters of circular bacteria growing in the eggs28. To prove that this bacterium was the
actual cause of infection, he inoculated guinea pigs and mice with pus taken from patients. These
animals developed similar symptoms, abscesses, and diseases as the patients. He named this new
bacterium Staphylococcus (staphyle meaning “bunch of grapes” and kokkos meaning berry),
based on its appearance under a microscope28,29. Four years later, when the German surgeon
Anton Rosenbach grew this new bacterium on media, he discovered two different strains through
different pigmentation of the colonies. He named the one that had a golden appearance S. aureus
and the white form S. albus (later renamed S. epidermis), and thus, Rosenbach is often credited
as the discoverer of S. aureus28.
The main habitat of S. aureus is the nose and skin of warm-blooded animals27. It is a
persistent resident on 20%, and found intermittently on ~60%, of the human population30.This
bacterium produces toxins and super-antigens that cause a wide range of diseases including toxic
shock syndrome, scarlet fever, scalded skin syndrome, endocarditis, necrotizing pneumonia,
food-borne illnesses, skin infections, and sepsis27,31–33. In 2011, the CDC reported ~80,000 lifethreatening S. aureus infections in the United States
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33

. In fact, more people die in the United

States from these infections than from HIV/AIDS each year34. S. aureus is especially challenging
to treat for two reasons: 1) it is capable of causing widespread infections by “hiding” from the
immune system through its multiple and redundant virulence factors and 2) its increasing
antibiotic resistance27,35,36.
S. aureus is a highly promiscuous organism capable of acquiring resistance and virulence
genes from other bacterial species through horizontal gene transfer. Antibiotic resistance can also
arise through mutations that alter the structure of an antibiotic target27,30,35,36. Almost as soon as
the β-lactam antibiotic penicillin was introduced, strains of penicillin-resistant S. aureus
arose31,36. To fight those infections, methicillin (a derivative of penicillin) was introduced, but
again resistance arose. Methicillin-resistant Staphylococcus aureus (MRSA) acquired a mutation
in the penicillin-binding protein MecA that was no longer able to bind to β-lactam drugs27,36,37.
Originally, MRSA was only contracted within a hospital setting and was thus called hospitalassociated MRSA; however, as early as 1990, MRSA was found in patients who had not been to
a hospital nor in contact with anyone who had been, and consequently community-associated
MRSA emerged31,36. At that time the “antibiotic of last resort”, vancomycin, was the only
remaining antibiotic that could reliably be used to treat MRSA infections38. Subsequently, strains
of S. aureus acquired vancomycin resistance from enterococci bacteria, and depending on the
exact genes acquired, became either less sensitive to or fully resistant to vancomycin27,36. In
addition, there are other strains of MRSA that are on the rise such as epidemic MRSA and
livestock-associated MRSA35. Therefore, there is a great need to discover novel antibiotic targets
to treat infections of these super resistant strains of S. aureus, as well as other multidrug-resistant
pathogenic bacteria. These targets could be proteins essential to the survival of the pathogen or
virulence factors that allow the pathogen to cause disease.
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viii. Phosphoglycolate Phosphatase in Staphylococcus aureus
A study by Begun et al. to identify novel S. aureus virulence factors uncovered several key
virulence factors, including a pNppase family member39. In this study, they used a
Caenorhabditis elegans killing model, which highly correlates virulence factors that kill
C. elegans to those involved in pathogenesis of vertebrate models39. Through screening 2,950
S. aureus mutants, they identified 145 mutants that had attenuated virulence. Most of these
virulence factors had already been identified, but five were not previously known39. These five
mutants with attenuated virulence were next studied in a murine renal abscess model in which
only one, SAV0929 which they identified as NagD, showed a significant decrease in virulence39.
Begun et al. misannotated SAV0929 as NagD nucleoside monophosphatase based simply on
sequence similarity; however, we show, in this thesis, that SAV0929 is instead a PGPase.
ix. Protein Moonlighting
The hypothesized role of this PGPase virulence factor may be explained by enzymatic
moonlighting. Many enzymes that were originally thought to be simply housekeeping enzymes,
such as those found in glycolysis, have been shown to perform unexpected secondary functions,
a concept referred to as moonlighting40,41. It is incongruous that a glycolytic enzyme, which is
found in nearly every organism, would increase virulence of a pathogen, but many of these
enzymes have been proven to be important virulence factors for pathogenic bacteria40,41. An
example of a glycolytic enzyme that has surprising moonlighting characteristics is triose
phosphate isomerase (TPI) from S. aureus40,42. Studies by Pancholi et al.43 and Ikeda et al.42,44
have shown that TPI from S. aureus is capable of binding to glucuronoxylomannan, the main
component of the capsule of Crytococcus neoformans, a microbe that S. aureus infects42. This
interaction was further investigated through the use of docking simulation experiments. The
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interaction between TPI and the capsule of C. neoformans would only be plausible if TPI was
expressed on the cell surface of S. aureus. Yamaguchi et al. used scanning immunoelectron
microscopy to confirm the presence of TPI on the cell surface of S. aureus45. Triose phosphate
isomerase’s moonlighting ability, as a cell surface protein, allows it to act as a virulence factor
through host cell adhesion.
Since phosphoglycolate is an inhibitor of TPI19,20, we hypothesize that phosphoglycolate
could reduce TPI’s adhesion to host cells thus reducing virulence, and that PGPase could act as a
virulence factor by degrading and removing phosphoglycolate, allowing TPI to act as an
adhesion virulence factor. Since Begun et al. showed SAV0929 to be a virulence factor for
S. aureus, it is crucial to characterize this enzyme to help defeat the spread of S. aureus,
including antibiotic resistance strains. The characterization of this enzyme as a phosphoglycolate
phosphatase is described in this thesis.
x. Methodology
Our research group is interested in characterizing the SAV0929 from S. aureus. When a
previous member of our lab cloned the gene, two mutations, I132V and Y209C, were introduced
during PCR (polymerase chain reaction) amplification of the gene from genomic DNA (ATCC).
Rather than risk introducing mutations again via PCR, we could have chosen to either perform
site-directed mutagenesis or design a synthetic gene. Because there were two mutations to
correct, we decided to design a synthetic gene (Figure 6).
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PGPase mutant MKQYKAYLIDLDGTMYMGTDEIDGAKQFIDYLNNKDIPHLYVTNNSTKTPEQVTEKLRE
PGPase wt
MKQYKAYLIDLDGTMYMGTDEIDGAKQFIDYLNNKDIPHLYVTNNSTKTPEQVTEKLRE
* *
**
I
II
PGPase mutant MNIDAKPEEVVTSALATAEYISEQSPGASVYMLGGSGLNTALTEAGLEIKDDEHVDYVV
PGPase wt
MNIDAKPEEVVTSALATAEYISEQSPGASVYMLGGSGLNTALTEAGLEIKDDEHVDYVV
PGPase mutant IGLDEKVTYEKLAVATLGVRNGATFISTNPDVSIPKERGLLPGNGAITSVVSVSTGIQP
PGPase wt
IGLDEKVTYEKLAIATLGVRNGATFISTNPDVSIPKERGLLPGNGAITSVVSVSTGIQP
PGPase mutant QFIGKPEPIIMIKALEILGLDKSEVAMVGDLCDTDIMSGINVGMDTIHVQTGVSTLEDV
PGPase wt
QFIGKPEPIIMIKALEILGLDKSEVAMVGDLYDTDIMSGINVGMDTIHVQTGVSSLEDV
*
**
*
III
IV
PGPase mutant QNKNVPPTYSFKDLNEAIAELEK
PGPase wt
QNKNVPPTYSFKDLNEAIAELEK

PGPase mutant QTGVSSLEDVQNKNVPPTYSFKD
PGPase
wt
QTGVSSLEDVQNKNVPPTYSFKD
Figure
6: Sequence
alignment
of Wild-Type and mutated PGPase from S. aureus. The sequence alignment
comparing the normal (wild-type) protein sequence for the phosphoglycolate phosphatase (PGPase) from S. aureus
and the protein sequence of the enzyme that had previously been characterized in the lab. The HAD motifs are
highlighted in yellow while the two mutations are noted in green. The mutations are I132V and Y209C.

A synthetic gene was designed that matched the sequence of SAV0929 (gene encoding the
PGPase) from S. aureus Mu50. Restriction sites for XbaI and NdeI were added to the 5’ end of
the gene and restriction sites for BamHI-HF and HindIII were added to the 3’ end of the gene,
for subcloning. SAV0929 contains a NdeI site and a HindIII site, thus two silent mutations were
introduced to remove these sites without changing the encoded amino acids (Figure 7). This
synthetic gene was delivered in the plasmid pMAT-SaPGPase.
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Figure 7. Predicted restriction sites for wildtype gene and synthetic gene. (a. wild type b. synthetic gene)
Restriction sites are shown for BamHI, HindIII, NdeI, and XbaI enzymes.

Figure 8. pET19b cloning and expression region. The region of the pET19b vector containing the T7 promoter
and terminator sequence, lac operator, His Tag, and various restriction sites.

This synthetic gene was subcloned into pET11b and pET19b plasmids. Both of these
expression systems include a T7 lac promoter/operator for overexpression (see Figure 8)46. The
lac operator is downstream of the promoter and allows for the binding of the lac repressor,
inhibiting transcription by preventing T7 RNA polymerase from binding, thus reducing basal
expression. An E. coli lac promoter controls transcription of the T7 RNA polymerase gene that is
encoded in (DE3) strains of E. coli. Lac promoters can be induced by the addition of isopropyl
β-D-thiogalactopyranosidase (IPTG)46. The structure of IPTG is similar to allolactose, a natural
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inducer for the lac promoter. IPTG binds to the lac repressor, allowing the T7 RNA polymerase
gene to commence transcription. pET19b also contains a sequence 5’ to the NdeI restriction site
that codes for a string of 10 histidines to create a His•Tag on the N-terminal end of the protein46.
Figure 9 shows schematics of pET11b, pET19b, and pMAT-SaPGPase while Figure 10 shows
the process of subcloning.
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Figure 9: Plasmid maps of pET11b, pET19b, and pMAT-SaPGPase. pET11b containing a T7 lac promoter.
pET19b containing a T7 lac promoter and a His•Tag coding sequence. pMAT-SaPGPase containing SAV0929.
EcoRV, NdeI, XbaI, HindII, and BamHI restriction sites are shown for all plasmids.
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Figure 10. Schematic of SaPGPase subcloning. SaPGPase subcloned into pET19b and pET11b plasmids.

Once the PGPase gene was subcloned into pET11b and pET19b (His•Tag), the PGPase was
overexpressed and purified. Production of protein was accomplished by overexpression in E.
coli (DE3) by induction with IPTG. The cells were lysed via freeze-thaw (untagged protein) or
sonication (His•Tagged protein). This was followed by Ni-NTA affinity chromatography for the
His•Tagged protein and size exclusion chromatography for both proteins.
Ni-NTA affinity chromatography exploits the fact that nickel readily binds to imidazole (the
R group of histidine)47. By creating an enzyme with a poly-histidine tag, the enzyme will bind to
the Ni-NTA resin, allowing other proteins to pass through the column and isolating the
His•Tagged protein. By increasing the imidazole concentration of the solution, the imidazole can
outcompete and displace the His•Tagged protein from the column. The sample is dialyzed to
remove free imidazole. Dialysis separates molecules based on molecular size; the membrane of
the dialysis cassette allows small molecules to passively diffuse through the membrane following
a concentration gradient while blocking larger (macro)molecules. A “stepwise” approach was
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utilized to lower the imidazole concentration slowly to avoid protein denaturation and
precipitation.
In size exclusion chromatography, also known as gel filtration chromatography, a column
filled with porous beads is used to separate macromolecules based on molecular weight48.
Smaller molecules are able to enter the porous beads; as such, their passage through the column
is ultimately slowed down. Since larger molecules are unable to enter the beads, they move
quickly around the beads and thus move through the column at a faster rate. Not only does this
technique readily separate macromolecules according to size, but this technique can also be used
to approximate the molecular weight of the macromolecules in a sample48.
Once the S. aureus PGPase was purified, it could be characterized for substrate specificity
and conditions for optimal activity including pH optimum and divalent metal ion requirements.
These parameters were evaluated by the Ames assay, a colorimetric enzyme assay. In the Ames
assay, ammonium molybdate reacts with inorganic phosphate that is released by the enzymatic
activity of the PGPase to form a blue phosphomolybdo complex49. The intensity of the resulting
blue complex is proportional to the concentration of inorganic phosphate, where 50 nmols of
phosphate per mL will yield 1 OD at 780 nms49.
The final component to this project was to determine the kinetic values of the PGPase. This
included determining the Vmax, kcat, Km, and kcat/Km for the enzyme with 2-phosphoglycolate or
p-nitrophenyl phosphate as the substrate. Additionally, purified PGPase from S. aureus was sent
to our collaborator, Dr. Roger Rowlett (Colgate University), for x-ray crystallography structure
determination.
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II. Materials and Methods
i. Synthetic Gene Design
A synthetic gene was designed for the PGPase gene (sav0929) from S. aureus and the
plasmid containing the gene (pMAT-SaPGPase) was ordered from Life Technologies. Two silent
mutations were introduced into the gene to remove internal restriction sites. T381C removes an
NdeI site and G387A removes a HindIII site. An XbaI restriction site was added to the 5’ end of
the gene, while a BamHI restriction site was added to the 3’ end of the gene, followed by a
HindIII site. This gene was delivered in a plasmid (pMAT-SaPGPase) containing an ampicillin
resistance gene for selection. ~5 μg of lyophilized DNA was dissolved in 50 μL cold, sterile
water and incubated overnight at 4 °C.
ii. Transformations of pMAT-SaPGPase
1 μL of pMAT-SaPGPase was added to 50 μL DH5α (Novagen) competent cells. 5 μL of
pUC19 was added to one tube as the positive control. Samples were incubated on ice for 30
minutes followed by a 25 second heat shock in a 37 °C water bath. Immediately following, the
samples were placed on ice for at least two minutes. 1 mL of sterile LB media was added to each
sample and incubated in a 37 °C water bath for 1 hour, with mixing by inversion every ten
minutes. The cells were plated on LB plates containing 0.1 mg/mL ampicillin and incubated at
37 °C for ~16 hours. One colony was streaked to single colonies and one single colony was
suspended in LB media containing 0.1 mg/mL ampicillin at 37 °C until 1.0 -1.5 OD (A600). A
freezer stock was made from the cell culture by the addition of 0.4 mL 80% glycerol to 1.6 mL
of cell culture and stored at -80 °C.
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iii. Plasmid Midiprep
E. coli DH5α cells containing pET11b, pET19b, or pMAT-SaPGPase were each grown in 50
mL of LB media containing 0.1 mg/mL ampicillin at 37 °C with shaking for ~16 hours. The cells
were harvested (12 tubes containing 3 mL culture) by centrifugation at 16,000 RCF (relative
centrifugal force) for 2 minutes at room temperature. Each tube of harvested cells were
resuspended in 100 μL of solution I (50 mM glucose, 25 mM Tris•HCl (pH 8.0), and 10 mM
EDTA). 200 μL of solution II (0.2 M sodium hydroxide and 1% SDS) was added to lyse the
cells. 150 μL of solution III (containing 3 M potassium and 5 M acetate) was used to precipitate
E. coli chromosomal DNA, leaving the plasmid DNA in solution.
DNase-free bovine pancreatic RNase A (Sigma) in TE buffer (10 mM Tris•HCl (pH 8.0), 1
mM EDTA) was added to the supernatant for a final concentration of 50 μg/mL RNase A, and
this was incubated at 37 °C for 30 minutes. Proteins were denatured and removed using a
phenol:chloroform (1:1) followed by a chloroform extraction. The plasmid DNA was
precipitated with 70% ethanol by freezing the solution (-72 °C) followed by centrifugation at
16,000 RCF at 4 °C for 30 minutes. The pellet, containing the plasmid DNA, was washed with
ice-cold 70% ethanol and dried using vacuum centrifugation. The pellet was dissolved in cold
sterile water. The plasmid DNA was precipitated with 13% polyethylene glycol (PEG) and 5 M
sodium chloride (on ice for approximately 18 hours) leaving tRNAs in the solution. The sample
was centrifuged at 16,000 RCF at 4 °C for 30 minutes, and the pellet containing the plasmid was
washed with ice-cold 70% ethanol. Pellets were resuspended in cold sterile water. The plasmid
DNA concentration was determined by absorbance at 260 nm with a UV-Vis spectrophotometer.
The plasmid DNA was analyzed further by 0.7% agarose gel electrophoresis.
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iv. Restriction Enzyme Digests
The PGPase synthetic gene was excised from 5000 ng pMAT-SaPGPase plasmid by
digestion with 40 units each XbaI and BamHI-HF or 40 units each NdeI and BamHI-HF
restriction enzymes (New England Biolabs). 5000 ng pET11b was digested using 40 units each
XbaI and BamHI-HF restriction enzymes, while 5000 ng pET19b was digested using 40 units
each NdeI and BamHI-HF restriction enzymes. Each plasmid was also digested with each of the
enzymes separately to verify efficiency. The double-digestion reactions were incubated at 37 °C
for 2 hours. The success of the digestions were verified by gel electrophoresis of the samples that
were digested with each individual enzyme, separately. The double-digested samples were gel
purified using the protocol in the GeneClean kit (MPBiomedicals). The final concentrations of
the digested plasmids were estimated by comparing to molecular weight markers and plasmid
standards via agarose gel electrophoresis.
v. Ligation
The PGPase synthetic gene, with digested ends, was ligated into pET11b and pET19b
plasmids, to create pETSaPGPase and pET19SaPGPase, respectively, using 0.5 units T4 DNA
ligase (Invitrogen) at 15 °C for 24 hours. The ratio of plasmid to gene was varied (Table 1), with
a 1:1 ratio theoretically being preferred. Ligations contained digested plasmid, digested gene,
ligase buffer, and ligase.
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Table 1: Ligations of SaPGPase into pET11b or pET19b.
Ligation Mixture

pET11b

pET19b

pUC

Ratio
pET11ba pET19bb SaPGPasec
(plasmid:gene)
(ng)
(ng)
(ng)

A

1:0

150

-

0

B

2:1

150

-

11

C

1:1

150

-

22

D

1:2

150

-

44

E

1:4

150

-

88

F

1:0

-

150

0

G

2:1

-

150

11

H

1:1

-

150

22

I

1:2

-

150

44

J

1:4

-

150

88

--

--

--

--

--

a

: pET11b is 5676 basepairs
b
: pET19b is 5717 basepairs
c
: Sa PGPase is 3208 basepairs

vi. Transformation of E. coli DH5α with pETSaPGPase and pET19SaPGPase
E. coli DH5α competent cells were transformed with the ligation mixtures (A-J) and grown
on LB plates containing 0.1 mg/ mL ampicillin for 16 hours at 37 °C. E. coli DH5α competent
cells transformed with pUC19 was used as a positive control. 5 μL of each ligation mixture was
added to 50 μL of DH5α E. coli competent cells, separately. Samples were incubated on ice for
30 minutes followed by a 25 second heat shock in a 37 °C water bath. Immediately following,
the samples were placed on ice for at least two minutes. 1 mL of sterile LB media was added to
each sample and incubated in a 37 °C water bath for 1 hour, with mixing by inversion every ten
minutes. The cells were plated on LB plates containing 0.1 mg/mL ampicillin and incubated at
37 °C for ~16 hours.
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vii. Plasmid miniprep
Colonies from each plate were selected to produce cell cultures from which to analyze the
cloned plasmids. Twelve to twenty-four different cultures containing a single colony were grown
separately in 5 mL LB media containing 0.1 mg/mL ampicillin at 37 °C with shaking for ~16
hours. 3 mL of each cell culture were harvested by centrifugation at 16,000 RCF at room
temperature for 2 minutes. Harvested cells were resuspended with solution I, lysed with solution
II, and E. coli chromosomal DNA was precipitated with solution III (solutions are the same as
above in the midiprep procedure). Phenol:chloroform (1:1) followed by chloroform extractions
denatured and removed proteins. The plasmid DNA was precipitated with 70% ethanol by
freezing and centrifuging. The pellets were rinsed with ice-cold 70% ethanol, dried by vacuum
centrifugation, and resuspended in sterile TE buffer (10 mM Tris•HCl (pH 8.0), 1 mM EDTA)
containing 20 μg/mL DNase-free bovine pancreatic RNase A (Sigma). The purified plasmids
were analyzed by 0.7% agarose gel electrophoresis; the size of the purified plasmids were
compared to purified pET11b or pET19b to determine if their bands ran slower on the gel and
thus potentially contained the gene of interest.
viii. Verification of subcloning
In order to verify that the gene was successfully cloned (creating pETSaPGPase and
pET19SaPGPase), the miniprepped samples were digested with restriction enzymes. 8 μL of
purified plasmid was digested with 20 units of each enzyme (either XbaI and BamHI-HF for
pETSaPGPase or NdeI and BamHI-HF). An additional digest using 40 units of EcoRV was
carried out for both pETSaPGPase and pET19SaPGPase. All reactions were carried out for 1
hour in a 37 °C water bath. All enzymes were added just prior to incubation. These reactions
were analyzed by gel electrophoresis. The double-digests would excise the gene from the
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plasmid. The single digest would cut the plasmids in two locations; the resulting bands would
differ if there was an inserted gene present. The predicted number and size of fragments was
determined. In this way, the ligations were confirmed.
The cell cultures that appeared to contain the successfully cloned gene were streaked to
single colonies on LB plates containing 0.1 mg/mL ampicillin and incubated at 37 °C for
~16 hours. One colony from each of a few select plates was picked to produce individual cell
cultures by incubating them in LB media containing 0.1 mg/mL ampicillin at 37 °C until 1.0-1.5
OD (A600) was reached. Individual freezer stocks were made from these cell cultures by the
addition of 0.4 mL 80% glycerol to 1.6 mL of cell culture and stored at -80 °C.
ix. Sequencing
Samples of pETSaPGPase and pET19SaPGPase purified from the -80 °C freezer stocks by
the midiprep procedure were sent to GENEWIZ for sequencing. Standard T7 promoter or T7
terminator primers were used as the primers. The resulting sequences were analyzed using Serial
Cloner to ensure the plasmids were correct.
x. Transformation into BLR (DE3)
After confirmation of the success of the subcloning via sequencing, E. coli BLR(DE3)
competent cells were transformed with purified pETSaPGPase and pET19SaPGPase, separately.
The transformed cells were plated onto LB plates containing 0.1 mg/mL ampicillin and
incubated at 37 °C for ~16 hours. Colonies were streaked to single colonies, which were used to
produce cell cultures (single colonies in LB media containing 0.1 mg/mL ampicillin at 37 °C
until 1.0 -1.5 OD (A600)). Individual freezer stocks were made from these cell cultures by the
addition of 0.4 mL 80% glycerol to 1.6mL of cell culture and stored at-80 °C.
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xi. Overexpression of SaPGPase and SaPGPase(HT) in BLR(DE3)
An inoculum of pETSaPGPase in E. coli BLR(DE3) was made by adding a scraping of the
freezer stock to 7.5 mL LB media containing 0.1 mg/mL ampicillin. The cell culture was grown
at 37 °C with shaking until the culture reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added
to prewarmed 50 mL LB media, containing 0.1 mg/mL ampicillin, and incubated at 37 °C with
shaking to a cell density of ~1 OD (A600). 40 mL of the 50 mL inoculum was added to
prewarmed 1L LB media containing 0.1 mg/mL ampicillin. The cell density was analyzed (A600)
every 30 minutes until it reached an OD of ~0.8, at which point the culture was induced with 5
mL 50 mg/mL IPTG. Prior to induction, 1.5 mL of culture was harvested and its pellet was
labeled TP=0 (Time Point 0) and stored at -80 °C. The induced cells were incubated for 3 hours
after induction, with a 1.5 mL sample harvested every hour (TP=1 hr, TP=2 hr, and TP=3 hr).
After three hours, the culture was harvested by centrifugation at 1,600 RCF at 4 °C for 15
minutes. The pellet was resuspended in cold buffered saline (50 mM Tris•HCl (pH 7.5), 86 mM
NaCl, 67 mM KCl), recentrifuged at 1,600 RCF at 4 °C for 15 minutes, and the pellet rinsed with
cold buffered saline. The final pellet was stored at -80 °C.
An inoculum of pET19SaPGPase in E. coli BLR(DE3) was made by adding a scraping of the
freezer stock to 7.5 mL LB media containing 0.1 mg/mL ampicillin. The cell culture was grown
at 37 °C with shaking until the culture reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added
to prewarmed 50 mL LB media, containing 0.1 mg/mL ampicillin, and incubated at 37 °C with
shaking to a cell density of ~1 OD (A600). 40 mL of the 50 mL inoculum was added to
prewarmed 1L LB media containing 0.1 mg/mL ampicillin. The cell density was analyzed every
30 minutes (A600) until it reached an OD of ~0.3, at which point the culture was incubated at 15
°C with shaking to an OD of ~0.6. At this point, the culture was induced with 5 mL 50 mg/mL

27

IPTG. Prior to induction, 1.5 mL of culture was harvested and its pellet was labeled TP=0 (Time
Point 0) and stored at -80 °C. The induced cells were incubated at 15 °C with shaking for an
additional ~24 hours. After ~24 hours, 1.5 mL culture was harvested (TP=24 hr). The rest of the
culture was harvested by centrifugation at 1,600 RCF at 4 °C for 15 minutes. The pellet was
resuspended in cold buffered saline, recentrifuged at 1,600 RCF at 4 °C for 15 minutes, and the
pellet rinsed with cold buffered saline. The final pellet was stored at -80 °C.
xii. Purification of SaPGPase from BLR(DE3)
a. Freeze-Thaw purification
The frozen pellet (stored at -80 °C) from the 1 L overexpression was thawed and resuspended
in 2 volumes (by weight) TED buffer (50 mM Tris•HCl (pH7.5), 1mM EDTA, 0.1 mM DTT).
The freeze-thawed sample was centrifuged at 9,100 RCF for 20 minutes at 4 °C. The supernatant
was separated from the pellet. The pellet was resuspended in the same volume of TED buffer,
frozen, thawed and centrifuged. The freeze-thawed supernatants were pooled together (~8.0 mL)
and ammonium sulfate was added to a final concentration of 80%. The sample was centrifuged at
14,200 RCF for 30 minutes at 4 °C. The supernatant was decanted and the pellet resuspended in
1 mL TED buffer.
b. Size exclusion chromatography
A S-100 sephacryl HR column (3 cm diameter × 80 cm length) was poured and equilibrated
with 400 ml buffer A (250 mM NaCl, 50 mM Tris•HCl (pH 7.5), 1mM EDTA, 0.1 mM DTT).
The concentrated, partially purified SaPGPase was loaded onto the column and proteins were
eluted with 200 ml buffer A, while collecting 2 mL fractions. A280/A260 was measured for each
fraction. The collected 2 ml fractions were analyzed for PGPase activity by an enzyme assay
with p-nitrophenyl phosphate (pNpp), a substrate-analog: in eppendorf tubes, 1 μL of the fraction
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was added to 1 μL of 1M MES•NaOH (pH 6.0), 1 μL 100 mM MgCl2, 1 μL 100 mM pNpp, and
6 μL H2O; the fractions that caused the reactions to produce p-nitrophenol became yellow in
color. Those fractions containing enzymatic activity were examined by SDS-PAGE. Those
fractions containing “visually” pure SaPGPase were pooled together. The protein in the pooled
sample was precipitated with 80% ammonium sulfate and centrifuged at 14,200 RCF for 20
minutes at 4 °C. The supernatant was separated from the pellet and the pellet containing
SaPGPase was resuspended in 500 μL TED buffer.
xiii. Purification of SaPGPase(HT) in BLR(DE3)
a. Cell lysis by sonication
The pellet from the 1 L overexpression was resuspended in 2 volumes (by weight) 20 mM
Tris•HCl (pH 8.0), placed back at -80 °C for at least one hour and thawed, to assist in cell lysis.
Cells were lysed by sonication using a Branson sonicator (output of 6.5 and 50% duty cycle), in
15-second intervals for a total of 10 minutes. Sonicated samples were centrifuged at 14,200 RCF
for 30 minutes at 4 °C. The supernatant was separated from the pellet, and each was labeled as
sonicated supernatant or sonicated pellet, respectively. Pellets were resuspended in 2 volumes of
20 mM Tris•HCl (pH 8.0). All fractions (whole cell crude extract, sonicated supernatant, and
sonicated pellet) were stored at -80 °C.
b. Ni-NTA His•Tag affinity chromatography
Twenty milliliters of Ni2+ affinity resin (Novagen) suspension was added to a column
(Biorad) and rinsed with ~200 mL binding buffer (5 mM imidazole, 20 mM Tris•HCl (pH 8.0),
500mM NaCl). The sonicated supernatant was loaded onto the column, and 100 mL wash buffer
(60 mM imidazole, 20 mM Tris•HCl (pH 8.0), 500 mM NaCl) was used to elute all of the E. coli
proteins, leaving the His•Tagged SaPGPase protein bound to the resin. The column was rinsed
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with 50 mL elute buffer (250 mM imidazole, 20 mM Tris•HCl (pH 8.0), 500 mM NaCl) to elute
2 mL fractions containing the His•Tagged SaPGPase protein. The protein concentration of each
fraction was determined by a Bradford assay and the fractions containing protein were analyzed
by SDS PAGE.
Fractions containing the His•Tagged SaPGPase protein and devoid of most other proteins
were combined and dialyzed using a Slide-A-Lyzer (10 kD MWCO) cassette (Pierce). A “step
down” dialysis procedure was used: dialysis in buffer 1 (100 mM imidazole, 250 mM NaCl, 20
mM Tris•HCl (pH 7.5)), followed by buffer 2 (50 mM imidazole, 250 mM NaCl, 20 mM
Tris•HCl (pH 7.5)) each for 1 hour, followed by buffer 3 (250 mM NaCl, 50 mM Tris•HCl (pH
7.5), 1 mM EDTA, 0.1 mM DTT) overnight. This dialysis process was necessary to avoid
protein denaturation and precipitation. The dialyzed protein solution was concentrated using
Amicon Ultra Centrifugal filter units (Millipore) centrifuged at 2,300 RCF at 4 °C until the final
volume was ~0.5-1.0 mL.
c. Size exclusion chromatography
A S-100 sephacryl HR column was prepared as described above. SaPGPase(HT) was loaded
onto the column and proteins were eluted with 200 ml of buffer A, while collecting 2 mL
fractions. Fractions were analyzed for SaPGPase(HT) as described above. Those fractions
containing enzymatic activity were examined by SDS-PAGE. Those fractions containing
“visually” pure SaPGPase(HT) were pooled together. The pooled protein solution was
concentrated using Amicon Ultra Centrifugal filter units (Millipore) centrifuged at 2,300 RCF at
4 °C until the final volume was ~1.0 mL.
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xiv. Analysis of protein purification
a. SDS PAGE analysis
All time point samples were resuspended in H2O (100 μL per OD). Each whole cell crude
extract, freeze-thawed supernatant, freeze-thawed pellet, sonicated supernatant, and sonicated
pellet was diluted to 0.1x with 20 mM Tris•HCl (pH 8.0). 5 μL of each time point or 0.1x
sample, 10 μL 20 mM Tris•HCl (pH 8.0), and 5 μL 4x protein loading buffer (200 mM Tris•HCl
(pH 6.8), 40% glycerol, 8% SDS, 400 mM DTT, and 0.08% bromophenol blue dye) were mixed
together and boiled for 10 minutes. The samples were analyzed by SDS PAGE (100 V for 20
minutes followed by 300 V for ~30-35 minutes). The gel was stained with Coomassie blue dye,
and de-stained with destain I (45% methanol, 9% acetic acid) for ~10 minutes followed by
destain II and Kimwipes (10% methanol and 10% acetic acid) overnight. The gel was placed in
drying solution (30% methanol and 5% glycerol) for 1 hour, and dried between cellophane
membranes.
b. Bradford assay
Solution containing protein (typically 5-20 μL) was added to 800 μL of water and mixed
well. To this mixture, 200 μL Bradford dye (BioRad) was added. Protein concentration was
determined by measuring A595 and using a standard curve of A595 as a function of BSA
concentration (see appendix).
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xv. Enzyme characterization
a. Determination of specific activity
The standard reaction mixture contained 50 mM MES•NaOH (pH 6.0), 10 mM MgCl2, 1 mM
DTT and either 4 mM pNpp or 4 mM 2-phosphoglycolate (2-PG) in 50 µl. Reactions with
varying enzyme amounts were carried out for 30 min at 37 ºC and quenched with 250 µl 4 mM
EDTA. Diluent (1 mg/mL BSA, 10% glycerol, 50 mM Tris (pH7.5), 1 mM DTT, and 1 mM
EDTA) was used in place of the enzyme in the negative control. The Ames and Dubin
colorimetric assay49 was used to measure the concentration of inorganic phosphate released by
the enzyme. Briefly, 600 μL 0.42% ammonium molybdate in 1 N H2SO4 mixed with 100 μL
10% ascorbic acid was added to 300 μL quenched reaction mixture. This 1 mL mixture was
incubated at 42 °C for 20 minutes and blue ammonium-molybdo-phospho complex was
measured at A780. Phosphate was quantified by: 50 nmol phosphate yields 1 OD at A780.
b. pH optimization
The standard reaction mixture consisted of 50 µl of 10 mM MgCl2, 1 mM DTT and 4 mM
pNpp or 4 mM 2-PG. 50 mM acetate (pH 4-5.5) 50 mM MES•NaOH (pH 5.0-7.0), or 50 mM
glycine (pH 8.0-10.0) were added to determine the pH optimum of the enzymatic reaction.
Reactions with varying enzyme concentrations were carried out for 30 minutes at 37 ºC and
quenched with 250 µl 4 mM EDTA. The Ames and Dubin colorimetric assay49 was used to
measure the concentration of inorganic phosphate released by the enzyme, as described above.
c. Metal ion preference
The standard reaction mixture consisted of 50 µl of 50mM MES•NaOH (pH 6.0) with 1 mM
DTT and 4 mM pNpp or 4 mM 2-PG. MgCl2, MnCl2, ZnCl2, CaCl2 or CoCl2 were added to
1mM or 10 mM divalent metal ion concentrations. Reactions were carried out for 30 minutes at
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37 ºC and quenched with 250 µl 4 mM EDTA. The Ames and Dubin colorimetric assay49 was
used to measure the concentration of inorganic phosphate released by the enzyme, as described
above.
d. Metal ion concentration optimization
Enzyme assays were carried out for solutions with concentrations of MgCl2 ranging from
1 mM to 50 mM. The standard reaction mixture consisted of 50 µl of 50 mM MES•NaOH (pH
6.0), 1 mM DTT and 4 mM pNpp or 4 mM 2-PG. Varying concentrations of MgCl2 were used
for each of the reaction mixtures. The reactions were carried out for 30 minutes at 37 ºC and
quenched with 250 µl 20 mM EDTA. Note that more EDTA was needed in these assays to
chelate the larger concentrations of Mg2+. The Ames and Dubin colorimetric assay49 was used to
measure the concentration of inorganic phosphate released by the enzyme, as described above.
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e. Substrate specificity
The standard reaction mixture consisted of 50 µl of 50mM MES•NaOH (pH 6.0),
10 mM MgCl2, and 1 mM DTT. 2 μL 100 mM substrate was chosen from a substrate library
stored at -80 °C (Table 2). Reactions were carried out for 30 minutes at 37 ºC and quenched with
250 µl 4 mM EDTA. The Ames and Dubin colorimetric assay49 was used to measure the
concentration of inorganic phosphate released by the enzyme, as described above.
Table 2: Substrates used to determine enzyme specificity

2,3-diphosphoglycerate
2-phosphoglycerate
2-Phosphoglycerol
2-phosphoglycolate
3-phosphoglycerate
3-phosphoglycerol
Arabinose-5-phosphate
DHAP
Fructose-1,6-bisphosphate
Fructose-1-phosphate
Fructose-2,6-bisphosphate
Fructose-6-phosphate
Glucosamine-1-phosphate
Glucosamine-6-phosphate
Glucose-1,6-bisphosphate
Glucose-1-phosphate
Glucose-6-phosphate
Glyceraldehyde phosphate

Histidine phosphate
Mannose-1-phosphate
Mannose-6-phosphate
NADP
NADPH
NAG-1-phosphate
NAG-6-phosphate
o-Phospho-L-Arginine
o-Phospho-L-Serine
o-Phospho-L-Threonine
o-Phospho-L-Tyrosine
phosphoenolpyruvate
phosphocreatine
phosphoinositides
phosphoinositol
phosphoryl ethanolamine
phosphorylcholine
Pyridoxal phosphate
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p-nitrophenly phosphate
Pyridoxamine Phosphate
Ribose-5-phosphate
Ribulose-5-phosphate
Thiamine diphosphate
Thiamine monophosphate
Thiazole phosphate
Trehalose-6-phosphate
Phosphoribosyl pyrophosphate
dCMP
dAMP
dGMP
dTMP
CMP
AMP
GMP
UMP

f. Kinetics
Enzyme assays were carried out for reactions with 0.1 mM to 40 mM pNpp or 0.1 mM to
20 mM 2-PG. The standard reaction mixture consisted of 50 µl of 50mM MES•NaOH (pH 6.0),
10 mM MgCl2, and 1 mM DTT. The reactions were carried out for 30 minutes at 37 ºC and
quenched with 250 µl 4 mM EDTA. The Ames and Dubin colorimetric assay49 was used to
measure the concentration of inorganic phosphate released by the enzyme, as described above.
The results were used to generate nonlinear regression and Lineweaver-Burke plots. Kinetic
values were determined using the program EnzymeKinetics.
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III. Results and Discussion
i. Plasmid Purification
The pMAT-SaPGPase, pET19b, and two samples of the pET11b plasmids were purified from
E. coli DH5α competent cells. Two samples of pET11b were purified due to lower yield. Upon
purification, the quantities of the purified plasmids (Table 3) were determined by the following
equation:
DNA concentration (ng/μL) =
Table 3: Quantification of pMAT-SaPGPase, pET19b, and pET11b.

[DNA] Volume DNA
(ng/μL)
(μL)
(μg)
pMAT-SaPGPase
365
120
40
Plasmid

pET19b

255

120

31

pET11b

125

120

15

pET11b

130

120

16

Plasmid purity is displayed in Figure 11. Previously purified samples of pET11b or pET19b
were used as positive controls. The intensity of the bands for the newly purified plasmids are
approximately the same as the intensity of the bands for the control plasmids in Figure 11A and
11B, while the intensity of the band for the newly purified plasmid is approximately twice that of
the band for the control in Figure 11C. The bands are sharp single bands indicating good purity.
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Figure 11: Plasmid midipreps of pMAT-SaPGPase, pET19b, and pET11b.
A: pMAT-SaPGPas. Lane 1: λ HindIII molecular weight markers (MWM), Lane
2: 100 ng previously purified pET11b, Lane 3: 100 ng pMAT-SaPGPase.
B: pET19b and pET11b. Lane 1: λ HindIII MWM, Lane 2: 100 ng pET19b,
Lane 3: 100 ng of previously purified pET19b, Lane 4: 100 ng previously
purified pET11b, Lane 5: 100 ng pET11b. C: pET11b. Lane 1: λ HindIII MWM,
Lane 2: 100 ng pET11b, Lane 3: 100 ng of previously purified pET11b.
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ii.

Plasmid Digestion and Purification
The pET11b plasmid and a portion of the pMAT-SaPGPase plasmid were both digested with
XbaI and BamHI-HF restriction enzymes while pET19b and another portion of the
pMAT-SaPGPase were digested with NdeI and BamHI-HF. These digests excised the PGPase
gene from pMAT-SaPGPase and created comparable restriction “sticky ends” on the gene and
within the pET plasmids. Single digests of each of the plasmids by the individual restriction
enzymes

(either

NdeI,

BamHI-HF,

or

XbaI)

were

complete

within

1

hour

(Figure 12). If the single digests were each complete, then it could be assumed that the double
digests were complete as well, since all were carried out under identical conditions. Singly
digested pET11b and pET19b plasmids ran on a gel as expected for linear DNA of ~5.7 kbp,
while the singly digested pMAT-SaPGPase ran on a gel as expected for linear DNA of ~3.2 kbp.
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Figure 12: Single restriction digests of pMAT-SaPGPase, pET11b, and pET19b.
A: pMAT-SaPGPase. Lane 1 & 5: λ HindIII MWM, Lane 2 100 ng pMAT-SaPGPase, Lane 3:
pMAT-SaPGPase digested with XbaI, Lane 4: pMAT-SaPGPase digested with BamHI-HF.
B: pET11b. Lane 1: λ HindIII MWM, Lane 2: 100 ng pET11b, Lane 3: pET11b digested with
XbaI, Lane 4: pET11b digested with BamHI-HF. C: pMAT-SaPGPase and pET19b. Lane 1 & 8: λ
HindIII MWM, Lane 2: 100 ng pMAT-SaPGPase, Lane 3: pMAT-SaPGPase digested with NdeI,
Lane 4: pMAT-SaPGPase digested with BamHI-HF, Lane 5: 100 ng pET19b, Lane 6: pET19b
digested with NdeI, Lane 7: pET19b digested with BamHI-HF
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The double digested samples of pMAT-SaPGPase, pET11b, and pET19b were purified on an
agarose gel, and the excised PGPase gene and digested pET11b and pET19b were extracted from
the gel and further purified using the GeneClean kit (Figure 13).

Figure 13: Gel purification of double restriction digests of pMAT-SaPGPase, pET11b, and
pET19b. A: pMAT-SaPGPase. Lane 1: λ HindIII MWM, Lanes 2 & 3: pMAT-SaPGPase digested
with XbaI and BamHI-HF. B: pET11B. Lane 1: λ HindIII MWM, Lanes 2 & 3: pET11b digested
with XbaI and BamHI-HF. C: pMAT-SaPGPase and pET19b. Lanes 1 & 6: λ HindIII MWM,
Lanes 2 & 3: pMAT-SaPGPase digested with NdeI and BamHI-HF, Lanes 4 & 5: pET19b
digested with NdeI and BamHI-HF.
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The concentrations of the purified digested gene and plasmids were estimated by comparing
to standards on agarose gels (Figure 14). The estimated concentrations were as follows: purified
digested pET11b was ~150 ng/μL, SaPGPase excised with XbaI and BamHI-HF was ~50 ng/μL,
purified digested pET19b was ~150 ng/μL, and SaPGPase excised with NdeI and BamHI-HF
was ~50 ng/μL.

Figure 14: Digested, gel-purified, gene-cleaned pET11b, pET19b, and SaPGPase. A: pET11b and SaPGPase
digested with XbaI and BamHI-HF. Lane 1: λ HindIII MWM, Lane 2: 100 ng pET11b, Lane 3: 1 μL digested, genecleaned pET11b, Lane 4: 2 μL digested, gene-cleaned pET11b, Lane 5: 1 μL digested, gene-cleaned SaPGPase,
Lane 6: 2 μL digested, gene-cleaned SaPGPase, Lane 7: 100 ng SaPGPase. B: pET19b and SaPGPase digested with
NdeI and BamHI-HF. Lane 1: λ HindIII MWM, Lane 2: 100 ng pET19b, Lane 3: 1 μL digested, gene-cleaned
pET19b, Lane 4: 2 μL digested, gene-cleaned pET19b, Lane 5: 100 ng SaPGPase, Lane 6: 1 μL digested, genecleaned SaPGPase, Lane 7: 2 μL digested, gene-cleaned SaPGPase.

iii. Ligation and Transformation
Ligations are most efficient when the concentration of plasmid is 10-20 ng/ μL and the ratio
of plasmid:gene is 1:150. The size of pET11b and pET19b is ~5.7 kbp, whereas the PGPase gene
is ~0.8 kbp. Therefore, if 150 ng of plasmid is used, then 22 ng of gene is required to achieve a
1:1 ratio of plasmid to gene. Because DNA concentrations could only be estimated, as described
above, the ratios of plasmid:gene were varied around a 1:1 ratio (see Table 4). Ligations A and F
contained only purified digested plasmid and no gene, as negative controls. Any colonies that
resulted from these ligations would be due to the re-ligation of plasmid, thus indicating less than
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100% cleavage by both restriction enzymes. The number of colonies that resulted from ligated
gene into plasmid was up to 450 times greater than ligated plasmid alone for pET11b and
approximately double for pET19b. pUC19 was used as a positive control for transformation.

Table 4: Ligations of SaPGPase into pET11b or pET19b.

pET11b

pET19b

pUC

Ligation
Mixture

Ratio
(plasmid:gene)

pET11ba
(ng)

pET19bb SaPGPasec
Coloniesd
(ng)
(ng)

A

1:0

150

-

0

1

B

2:1

150

-

11

18

C

1:1

150

-

22

158

D

1:2

150

-

44

~450

E

1:4

150

-

88

~360

F

1:0

-

150

0

140

G

2:1

-

150

11

~300

H

1:1

-

150

22

~315

I

1:2

-

150

44

~200

J

1:4

-

150

88

~200

--

--

--

--

--

Lawn

a

: pET11b is 5676 basepairs
: pET19b is 5717 basepairs
c
: SaPGPase is 3208 basepairs
d
: 50 μL transformed cell cultures on LB-Ampicillin plates.
b

Twelve colonies from plates B-E were analyzed for successful subcloning of pETSaPGPase
and twelve colonies from G-J were analyzed for successful subcloning of pET19SaPGPase. As
shown in Figure 15, both pETSaPGPase and pET19SaPGPase were successfully subcloned. Both
subclones contain ~6.5 kbp and thus run slower on the agarose gel as compared to the ~5.7 kbp
pET11b and pET19b.
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Figure 15: Screening of possible pETSaPGPase and pET19SaPGPase. A:
plasmid minipreps for pETSaPGPase. Lanes 1 & 14: 100 ng pET11b, Lanes 213: pETSaPGPase. B: plasmid minipreps for pET19SaPGPase. Lanes 1 & 14:
100 ng pET19b, Lanes 2,3,6,8-11, and 13 (boxed): pET19SaPGPase. Lanes 4,
5, 7, and 12: religated pET19b. Red arrows on the left side of the images
indicate the position of pET11b or pET19b, while the black arrows on the right
indicate the position of pETSaPGPase or pET19SaPGPase that have
successfully been cloned.
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iv. Verification of Subcloning
To verify that pETSaPGPase and pET19SaPGPase were successfully subcloned, EcoRV,
XbaI with BamHI-HF, and NdeI with BamHI-HF were used. As shown in Figure 16, EcoRV
produced bands of 4229 bp for all plasmids and a second band of either 1447-1488 bp for
pET11b/pET19b or 2196-2260bp for pETSaPGPase/pET19SaPGPase, indicating that the
PGPase gene of ~780 bp was successfully subcloned into both pET11b and pET19b. When XbaI
with BamHI-HF or NdeI with BamHI-HF were used, the enzymes excised the gene from
pETSaPGPase and pET19SaPGPase, producing fragments of 833 bp or 783 bp, respectively. The
double bands shown in Figure 16B were due to incomplete digestion by NdeI and BamHI-HF.

Table 5: Digestion patterns for pET11b, pET19b, pETSaPGPase, and pET19SaPGPase. using SerialCloner.

EcoRV
(bp)

XbaI & BamHI-HF
(bp)

NdeI & BamHI-HF
(bp)

pET11b

4229 + 1447

5599 + 77

------

pETSaPGPase

4229 + 2196

5599 + 822

------

pET19b

4229 + 1488

------

5706 + 11

pET19SaPGPase

4229 + 2260

------

5706 + 783
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Figure 16: Verification of pETSaPGPase and pET19SaPGPase subcloning.
A: pETSaPGPase. Lanes 1 & 10: λ HindIII MWM, Lane 2: pET11b digested with
EcoRV, Lanes 3-5: pETSaPGPase digested with EcoRV, Lane 6: pET11b digested with
XbaI & BamHI-HF, Lanes 7-9: pETSaPGPase digested with XbaI & BamHI-HF.
B: pET19SaPGPase. Lanes 1 &12: λ HindIII MWM, Lane 2: pET19b digested with
EcoRV. Lanes 3-6: pET19SaPGPase digested with EcoRV. Lane 7: pET19b digested
with NdeI & BamHI-HF, Lanes 8-11: pET19SaPGPase digested with NdeI &
BamHI-HF.
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v. Midiprep of pETSaPGPase and pET19SaPGPase
Midiprep purification was performed to purify pETSaPGPase and pET19SaPGPase from E.
coli DH5α. The DNA concentration was determined by A260 (Table 6). Purity and yield were
verified by agarose gel electrophoresis (Figure 17).

Table 6: Quantification of pETSaPGPase and pET19SaPGPase.

pETSaPGPase

DNA
(ng/μL)
235

Volume
(μL)
120

DNA
(μg)
28

pET19SaPGPase

220

120

26

Plasmid

Figure 17: Plasmid midipreps of pETSaPGPase and pET19SaPGPase.
Lanes 1 & 6: λ HindIII MWM, Lane 2: 100 ng pET11b, Lane 3: 100 ng
pETSaPGPase, Lane 4: 100 ng pET19b, Lane 5: 100 ng pET19SaPGPase

vi. Sequencing of pETSaPGPase and pET19SaPGPase
The sequence of pETSaPGPase and pET19SaPGPase were confirmed to be correct with the
incorporated gene sequence matching that of SAV0929 from S. aureus Mu50. Once the gene
sequence was confirmed, E. coli BLR(DE3) was transformed with pETSaPGPase and
pET19SaPGPase.
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vii. Overexpression of SaPGPase(HT) in E. coli BLR (DE3)
S. aureus PGPase(HT) was overexpressed in E. coli BLR(DE3) at 15 °C. The cells were
harvested 24 hours after induction with IPTG, and sonicated to produce the fractions shown in
Figure 18. SaPGPase(HT) expression is observed by the appearance of a major band between
the 25 and 37 kDa molecular weight markers (MWMs) upon induction. Only ~50% of the
SaPGPase(HT) was released from the cells, even after 10 minutes of sonication (either due to
protein insolubility or incomplete sonication. However, a sufficient quantity of SaPGPase(HT)
was in the sonicated supernatant; the sonicated supernatant contained 170 mg total protein.

Figure 18: Overexpression and solubility of SaPGPase(HT) from BLR(DE3). Lane 1:
MWMs, Lane 2: prior to induction, Lane 3: 24 hours after induction, Lane 4: crude extract, Lane
5: sonicated supernatant, Lane 6: sonicated pellet. The arrow indicates SaPGPase(HT).
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viii. Ni-NTA affinity chromatography of S. aureus PGPase(HT)
Sonicated supernatant containing SaPGPase(HT) was purified by Ni-NTA affinity
chromatography. Using a wash buffer containing 60 mM imidazole, all proteins were eluted
from the column with the exception of the SaPGPase(HT) bound to the Ni2+ through the
ten-histidine tag at the N-terminal end of the protein. The bound protein was eluted from the
column by increasing the imidazole concentration to 250 mM (elution buffer). As shown in
Figure 19, the SaPGPase(HT) was significantly purified with virtually all other protein eluting
with wash buffer and the SaPGPase(HT) eluting within a few fractions with the elution buffer.
Elution fractions 5-9 were pooled together and the imidazole was dialyzed out in a stepwise
manner as not to denature and precipitate the SaPGPase(HT). After dialysis, the sample was
concentrated with an Amicon filter unit (Millipore) to a volume of 1.4 ml with a protein
concentration of 33.3 mg/mL for a total of 47 mg protein.
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A
0.5
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0.35
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5
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B

Figure 19: Ni-NTA affinity chromatography of SaPGPase(HT). A: A595 (Bradford assay) vs.
fraction. B: SDS-PAGE. Lanes 1-3: wash fractions 2-4. Lanes 4-9: elution fractions 5-10. Lane 10:
MWMs.
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ix. Size exclusion chromatography of S. aureus PGPase(HT)
Size exclusion chromatography was used to remove any remaining impurities from
SaPGPase(HT). Figure 20 shows the analysis of fractions that were eluted from the column. The
fractions containing purified SaPGPase(HT)

(fractions 58-63) were pooled together and

concentrated using an Amicon filter unit (Millipore) to a final volume of 1.4 mL with a protein
concentration of 20.6 mg/mL for a total of 29 mg protein). The SaPGPase(HT) eluted from the
size

exclusion

column

in

fractions

that

corresponded

to

a

protein

standard

of

29 kDa, indicative that the SaPGPase(HT), with a monomeric mass of 29.3 kDa, is a monomeric
protein in solution (see appendix).
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A

B

Figure 20: Size exclusion chromatography of SaPGPase(HT). A: Absorbance (● A260, ■ A280) vs.
fraction. B: SDS-PAGE. Lane 1: MWMs, Lanes 2-10: fractions 57-65.
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x. Overexpression of SaPGPase in E.coli BLR(DE3)
S. aureus PGPase (without a His•Tag) was overexpressed in E. coli BLR(DE3) at 37 °C. The
cells were harvested 3 hours after induction with IPTG and underwent two rounds of freezing
and thawing to produce the fractions seen in Figure 21. SaPGPase expression is observed by the
appearance of a major band between the 25 and 37 kDa MWMs upon induction. Approximately
25% of the SaPGPase was released from the cells after one round of freeze-thaw. A second
round of freeze-thaw was able to release ~50% of the SaPGPase that remained in the first freezethaw pellet. The two freeze-thaw supernatants were pooled together for a protein concentration
of 5.75 mg/mL in a volume of 8.0 mL for a total of 46 mg protein.

Figure 21: Overexpression and solubility of SaPGPase from BLR(DE3). Lane 1: MWMs,
Lane 2: prior to induction, Lane 3: 1 hour after induction, Lane 4: 2 hours after induction, Lane 5:
3 hours after induction, Lane 6: crude extract, Lane 7: freeze-thaw supernatant, Lane 8: freezehaw pellet, Lane 9: second freeze-thaw supernatant, Lane 10 second freeze-thaw pellet. The arrow
indicates SaPGPase.
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xi. Ammonium sulfate concentration of SaPGPase
The freeze-thaw extract containing SaPGPase was concentrated by the addition of
ammonium sulfate to a final concentration of 80% (Figure 22), causing SaPGPase to precipitate.
The precipitant was resuspended in 1 mL TED buffer. The final protein concentration was 22.3
mg/mL in a volume of 1.7 mL for a total of 36 mg protein.

Figure 22: Ammonium sulfate concentration of SaPGPase
freeze-thaw extract. Lane 1: MWMs, Lane 2: 1 μL pooled
freeze-thaw extract, Lane 3: 1μL of concentrated SaPGPase.
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xii. Size exclusion chromatography of SaPGPase
Size exclusion chromatography was used to further purify the SaPGPase protein. Figure 23
shows the analysis of fractions that were eluted from the column. Two separate pooled fractions
were concentrated by 80% ammonium sulfate precipitation. The SaPGPase was separated into
two fractions due to the presence of another protein. The purer fraction, Fraction A (fractions
53-60) had a final volume of 1.7 mL with a protein concentration of 11.5 mg/mL for a total of
19.5 mg protein, while the less pure fraction, Fraction B (fractions 61-65) had a final volume of
0.6 mL with a protein concentration of 12.4 mg/mL for a total of 7.4 mg protein. As with the
SaPGPase(HT), the SaPGPase eluted from the size exclusion column in fractions that
corresponded to a protein standard of 29 kDa, indicative that the SaPGPase (with a monomeric
molecular mass of 27.9 kDa) is a monomeric protein (see appendix). The SaPGPase was not as
pure as the SaPGPase(HT), but its purity sufficed for comparison to the His•Tagged protein.
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A

B

Fraction A

Fraction B

Figure 23: Size exclusion chromatography of SaPGPase. A: Absorbance (● A260, ■ A280)
vs. fraction. B: SDS-PAGE. Lane 1: MWMs, Lanes 2-10: fractions 50, 55, 57, 59, 61, 63, 65,
68, and 71, respectively. Samples were pooled together based on purity into two fractions.
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xiii. Total Purification of SaPGPase(HT) and SaPGPase
The purpose of introducing the His•Tag to the end of the protein was to simplify purification
and increase the purity of the final enzyme. Figure 24 shows the overall purification of both
SaPGPase(HT) and SaPGPase. Tables 7 and 8 show the details of the purification of each
protein. As can be seen by comparing Figure 24A and Figure 24B, the addition of the His•Tag
did increase the purity of the enzyme.

Table 7: Purification of S. aureus PGPase(HT)

Purification Step
Sonicated Supe
Ni2+ Affinity
Size Exclusion

Volume Protein Concentration Total Protein
(mL)
(mg/mL)
(mg)
7.0
24.3
170
1.4
33.3
47
1.4
20.6
29

Table 8: Purification of S. aureus PGPase

Volume Protein Concentration Total Protein
(mL)
(mg/mL)
(mg)
Freeze-Thaw Supe
8.0
5.8
46
80% Ammonium Sulfate
1.7
22.3
38
Size Exclusion Fraction A
1.7
11.5
19
Size Exclusion Fraction B
0.6
12.4
7
Purification Step
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Figure 24: Purification of S. aureus PGPase(HT) and PGPase. A: SaPGPase(HT). Lane 1:
MWMs, Lane 2: crude extract, Lane 3: sonicated supernatant, Lane 4: Ni-NTA purified, Lane 5:
size exclusion purified. B: SaPGPase. Lane 1: MWMs, Lane 2: crude extract, Lane 3: pooled
freeze-thaw extract, Lane 4: 80% ammonium sulfate pellet, Lane 5: size exclusion fraction A,
Lane 6: 80% ammonium sulfate pellet, Fraction A.
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xiv. Characterization of S. aureus phosphoglycolate phosphatase
For all characterization and kinetics, a unit of enzymatic activity is defined as 1 mol of
substrate cleaved per minute. S. aureus PGPase and PGPase(HT) were characterized to
determine the best substrate, divalent metal ion, and pH needed to ensure optimal enzymatic
activity. Experiments were carried out first with the relatively inexpensive, biologically
non-natural, substrate-analog p-nitrophenyl phosphate to conserve the expensive and difficult to
obtain substrate 2-phosphoglycolate, though most of the data is reported for the biologically
significant 2-phosphoglycolate.
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a. Substrate Specificity
For both the native and His•Tagged versions of the PGPase, the best substrate is
2-phosphoglycolate. The next best substrate is the non-natural substrate-analog p-nitrophenyl
phosphate (Table 9). No other substrate from our substrate library had more than 5% relative
activity in comparison to 2-phosphoglycolate.

Table 9: Substrate specificity of SaPGPase
SaPGPase(HT)
Substrate

Specific Activity
(U/mg)

SaPGPase

Relative Activity

a

Specific Activity

(%)

(U/mg)

a

Relative Activity
(%)

2-phosphoglycolate

128.3

100

129.9

100

p-nitrophenyl phosphate

55.7

43

34.7

27

Phosphoenolpyruvate

6.2

5

4.8

4

fructose-1-phosphate

4.8

4

3.5

3

glucose-1,6-bisphosphate

4.7

4

1.1

1

2-phosphoglycerol

4.4

3

1.7

1

glyceraldehyde-3-phosphate

2.8

2

<1

<1

thiamine diphosphate

2.7

2

3.1

2

arabinose-5-phosphate

<1

<1

<1

<1

pyridoxal phosphate

<1

<1

<1

<1

3-phosphoglycerol

<1

<1

<1

<1

a

: One unit of enzyme hydrolyses 1 μmol of substrate per min.
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b. pH optimum
The pH optimum was determined using magnesium chloride as the metal ion cofactor and
2 phosphoglycolate as the substrate. Buffers of acetate (pH 4.0-5.5), MES•NaOH
(pH 5.0-7.0), and glycine (pH 8.0-10.0) were used. As shown in Figure 25, the enzyme has
optimal activity at pH 6.0.
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Figure 25: Effect of pH on PGPase activity. A: PGPase B: PGPase (HT). Reactions were carried out at 37 ˚C with
4 mM 2-phosphoglycolate, 10 mM Mg2+, 1 mM DTT. and 50 mM acetate (◊), 50 mM MES•NaOH (▲) or 50 mM
glycine (X) at various pH values. C: Overlay of the proteins with PGPase (◊, black line) and PGPase (HT)
(■, red line).
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c. Divalent metal ion requirements
S. aureus PGPase absolutely requires a divalent metal ion cofactor for activity. The best
metal ion cofactor was determined for PGPase(HT) with solutions of Mg2+, Mn2+, Co2+, Zn2+,
and Ca2+ ranging in concentration from 1-50 mM (Figure 26). The metal ion yielding the highest
activity was Mg2+ at a concentration of 10 mM. Mn2+ and Co2+ were the next best metals with
~20% relative activity, while Zn2+ and Ca2+ gave no activity.
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Figure 26: Effect of divalent metal ion concentration on PGPase(HT) activity. Reactions were carried out at
37 ˚C with 4 mM 2-phosphoglycolate, 50 mM MES•NaOH (pH 6.0), 1 mM DTT, 0.0021 μg PGPase(HT), and
either A: 1 (blue) or 10 (orange) mM Mg2+, Mn2+, Co2+, Zn2+, or Ca2+ or B: various concentrations of Mg2+ (◊),
Mn2+ (□), Co2+ (X), Zn2+ (▲), and Ca2+ ( ). Mg2+ gave optimal activity while Zn2+and Ca2+ gave no activity.

*
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S. aureus PGPase enzyme was tested using either 1 or 10 mM of Mg2+, Mn2+, Co2+, Zn2+, and
Ca2+. Of these, 10 mM Mg2+was shown to yield the highest activity, and a more complete range
of Mg2+ concentrations was used from 1- 50 mM (Figure 27). As with the PGPase(HT), PGPase
has optimal activity at 10 mM Mg2+, with Mn2+ and Co2+being the next best metals with ~40%
relative activity and virtually no activity with either Zn2+ or Ca2+.

A 100
Relative Activity (%)

80
60
40
20
0
Mg

B

Mn

Co

Zn

Ca

[M2+] (mM)
120

Relative Activity (%)

100
80
60
40
20
0
0

10

20 2+
30
[Mg ] (mM)

40

50

Figure 27: Effect of divalent metal ion concentration on PGPase activity. Reactions were carried out at 37 ˚C
with 4 mM 2-phosphoglycolate, 50 mM MES•NaOH (pH 6.0), 1 mM DTT, 0.003μg PGPase, and either A: 1 (blue)
or 10 (orange) mM Mg2+, Mn2+, Co2+, Zn2+, or Ca2+ or B: various concentrations of Mg2+. Mg2+ gave optimal
activity while Zn2+and Ca2+ gave no activity.
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d. Kinetic analysis of S. aureus PGPase(HT) and PGPase
Kinetic analysis was carried out for both forms of the enzyme to ensure that the addition of a
His•Tag did not interfere with enzymatic activity. Two different concentrations of the enzyme
were tested against varying concentrations of the substrate 2-phosphoglycolate for both native
and tagged PGPase. An additional analysis was performed using PGPase(HT) and p-nitrophenyl
phosphate. Vmax and Km values were determined from nonlinear regression graphs (Figures 28A,
29A, and 30A). The graphs show that both forms of the enzyme follow Michaelis-Menten
kinetics. The kcat was calculated under the assumption that the enzyme is a monomer (as
determined by size exclusion chromatography). The kinetic values (Vmax, Km, kcat, and kcat/Km)
are in Table 8. Comparison of the catalytic efficiencies (kcat/Km) of native and His•Tagged
enzyme shows that the addition of the His•Tag did not impact the enzymatic activity with kcat/Km
values of 163.5 ± 20.8 mM-1 • s.-1 and 176.4 ± 35.3 mM-1 • s.-1, respectively. It should be noted
that the apparent difference in kcat values is caused by different protein weights due to the
additional His•Tag (27.9 kDa versus 29.3 kDa).
Table 10: Kinetic values for PGPase. For 2-phosphoglycolate (PG), the standard phosphatase assay was used with
0.1-20 mM substrate. For p-nitrophenyl phosphate (pNpp), the standard phosphatase assay was used with
0.1-40 mM substrate. Vmax and Km were determined from a nonlinear regression analysis and kcat was calculated
from Vmax assuming that PGPase is a monomer with a molecular mass of either 27.8 kDa (untagged) or 29.3 kDa
(His•Tagged).

Enzyme

Substrate

Vmax (U/mg)

kcat (s-1)

Km (mM)

kcat/Km (mM-1• s.-1)

PGPase

PG

822.4 ± 27.0

382.4 ± 12.6

2.34 ± 0.22

163.5 ± 20.8

PGPase (HT)

PG

969.1 ± 51.8

556.8 ± 29.8

3.16 ± 0.47

176.4 ± 35.3

PGPase (HT)

pNpp

117.4 ± 2.7

67.5 ± 1.6

6.54 ± 0.45

10.3 ± 1.0
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Figure 28: Nonlinear regression and Lineweaver-Burke plot for S. aureus PGPase with 2-phosphoglycolate.
0.1-20 mM 2-PG with either 0.57 ng PGPase (▲) or 0.29 ng PGPase (■).
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Figure 29: Nonlinear regression and Lineweaver-Burke plot for S. aureus PGPase(HT)
2-phosphoglycolate . 0.1-20 mM 2-PG 0.83 ng PGPase (HT) (▲) or 0.17 ng PGPase(HT) (■).
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Figure 30: Nonlinear regression and Lineweaver-Burke plot for S. aureus PGPase(HT) with p-nitrophenyl
phosphate. 0.1-40 mM pNpp with either 17 ng PGPase(HT) (▲) or 8 ng PGPase(HT) (■).
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IV. Conclusions
Our lab has been systematically characterizing members of the pNppase subfamily of the
HAD superfamily. When Begun et al. reported a subfamily member from S. aureus that acted as
a virulence factor; we decided to characterize it next. The authors of the study identified the
protein as an ortholog of the NagD UMPase from E. coli due to similar amino acid sequence
alignment. However, we suspected this protein was not an UMPase, as it was no closer in
sequence to NagD than to the other subfamily members. The enzymatic activity of this protein
was not known prior to the work done for this thesis.
The S. aureus SAV0929 synthetic gene was designed and subcloned into pET11b and
pET19b plasmids for overexpression; subcloning into the pET19b plasmid incorporated a
His•Tag at the N-terminal end of the protein. Both forms of the protein (tagged and untagged)
have been expressed, determined to be soluble, purified, and characterized. Purification of the
native protein involved freeze-thaw cycles followed by concentration via ammonium sulfate.
Purification of His•Tagged protein involved sonication followed by Ni-NTA affinity
chromatography and concentration via centrifugal filtration. Both proteins were further purified
by size exclusion chromatography.
Enzyme assays have been done, for both forms of the protein, to determine substrate
specificity (2-phosphoglycolate is the best substrate), pH optimum (pH 6.0), and divalent metal
ion optimum (10 mM Mg2+). Kinetic values were determined with no significant difference
observed between the two forms of the protein. That, along with the same results for substrate
specificity, pH optimum, and divalent metal ion requirements indicates that the His•Tag does not
interfere with enzymatic activity. However, the His•Tag enabled us to purify the protein more
easily.
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We determined that the protein encoded by SAV0929 is a phosphoglycolate phosphatase and
not an UMPase like NagD. Thus showing that assigning function based on sequence similarity is
not always reliable and often the only way to determine function is to do the in vitro
experiments.
The study by Begun et al. demonstrated that the enzyme is a virulence factor, but exactly
how it confers virulence is not currently known. The phosphoglycolate phosphatase could be
present to degrade 2-phosphoglycolate created from the repair of oxidatively damaged DNA.
This would ensure the glycolytic enzyme triose phosphate isomerase is not inhibited, thus
allowing TPI to function normally in glycolysis as well as moonlighting as an adhesion factor.
Future work will involve phenotypic and complementation studies furthering the virulence
work by Begun et al.; however, that will require a collaboration with that research group. To
determine the protein’s structure, purified PGPase(HT) has been given to Dr. Roger Rowlett at
Colgate University for x-ray crystallography. The crystal structure will be immensely useful in
drug design if this enzyme is determined to be a reliable target for new antibiotics to combat
drug resistant strains of S. aureus.
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VII. Appendix

Figure 31: Size exclusion chromatography of protein standards.
Absorbance (● A260, ■ A280) vs. fraction. 200 kDa (β-amylase), 66 kDa (BSA), 29 kDa
(carbonic anhydrase) and 12.4 kDa (cytochrome C) peaks are indicated.
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Figure 32: Standard curve for Bradford protein analysis. Using BSA standard.
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